WO2015104658A3 - Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin - Google Patents

Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin Download PDF

Info

Publication number
WO2015104658A3
WO2015104658A3 PCT/IB2015/050113 IB2015050113W WO2015104658A3 WO 2015104658 A3 WO2015104658 A3 WO 2015104658A3 IB 2015050113 W IB2015050113 W IB 2015050113W WO 2015104658 A3 WO2015104658 A3 WO 2015104658A3
Authority
WO
WIPO (PCT)
Prior art keywords
dapagliflozin
amorphous
preparation
solid dispersion
amorphous solid
Prior art date
Application number
PCT/IB2015/050113
Other languages
French (fr)
Other versions
WO2015104658A2 (en
Inventor
Deepika PATHIVADA
Arshad Alam MOHAMMED
Original Assignee
Dr. Reddy’S Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy’S Laboratories Limited filed Critical Dr. Reddy’S Laboratories Limited
Publication of WO2015104658A2 publication Critical patent/WO2015104658A2/en
Publication of WO2015104658A3 publication Critical patent/WO2015104658A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Aspects of the present invention relate to process for preparation of amorphous form of dapagliflozin, amorphous solid dispersion of dapagliflozin together with one or more pharmaceutically acceptable carriers, process for its preparation and pharmaceutical composition thereof.
PCT/IB2015/050113 2014-01-08 2015-01-07 Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin WO2015104658A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN87/CHE/2014 2014-01-08
IN87CH2014 2014-01-08

Publications (2)

Publication Number Publication Date
WO2015104658A2 WO2015104658A2 (en) 2015-07-16
WO2015104658A3 true WO2015104658A3 (en) 2015-11-12

Family

ID=53524440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/050113 WO2015104658A2 (en) 2014-01-08 2015-01-07 Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin

Country Status (1)

Country Link
WO (1) WO2015104658A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3114115A4 (en) * 2014-03-06 2017-08-23 MSN Laboratories Private Limited Process for the preparation of (1s)-1,5-anhydro-1-c-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-d-glucitol and its solvate thereof
WO2016161995A1 (en) * 2015-04-08 2016-10-13 Zentiva, K.S. Solid forms of amorphous dapagliflozin
EP3349762B1 (en) 2015-09-15 2021-08-25 Laurus Labs Limited Co-crystals of sglt2 inhibitors, process for their preparation and pharmaceutical compositions thereof
US9845303B2 (en) 2015-10-19 2017-12-19 Cadila Healthcare Limited Process for the preparation of dapagliflozin
CN106727368A (en) * 2015-11-24 2017-05-31 上海星泰医药科技有限公司 A kind of Dapagliflozin pharmaceutical composition and preparation method thereof
KR102004488B1 (en) * 2015-12-11 2019-07-26 동아에스티 주식회사 Novel Solvates of Dapagliflozin or Methods for Preparing the Same
WO2017118945A1 (en) 2016-01-08 2017-07-13 Lupin Limited Premix of dapagliflozin and process for the preparation thereof
WO2017203229A1 (en) 2016-05-27 2017-11-30 Cipla Limited Dapagliflozin premixes
US11020412B2 (en) 2017-03-16 2021-06-01 Inventia Healthcare Limited Pharmaceutical composition comprising dapagliflozin
TR201918102A1 (en) * 2019-11-20 2021-07-26 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A solid pharmaceutical composition comprising amorphous dapagliflozin isolated from a polar solvent
EP4114365A1 (en) 2020-03-05 2023-01-11 KRKA, d.d., Novo mesto Pharmaceutical composition comprising sglt2 inhibitor
JP2023549669A (en) * 2020-10-27 2023-11-29 アイエスピー インヴェストメンツ エルエルシー Method and system for predicting properties of amorphous solid dispersions using machine learning

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008116179A1 (en) * 2007-03-22 2008-09-25 Bristol-Myers Squibb Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
EP2597090A1 (en) * 2011-11-28 2013-05-29 Sandoz AG Crystalline dapagliflozin hydrate
EP2529742B1 (en) * 2011-06-03 2013-11-20 ratiopharm GmbH Pharmaceutical composition comprising dapagliflozin and cyclodextrin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008116179A1 (en) * 2007-03-22 2008-09-25 Bristol-Myers Squibb Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
EP2529742B1 (en) * 2011-06-03 2013-11-20 ratiopharm GmbH Pharmaceutical composition comprising dapagliflozin and cyclodextrin
EP2597090A1 (en) * 2011-11-28 2013-05-29 Sandoz AG Crystalline dapagliflozin hydrate

Also Published As

Publication number Publication date
WO2015104658A2 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
EP3436482A4 (en) Antibodies, pharmaceutical compositions and methods
WO2016011222A3 (en) Circular polynucleotides
WO2016094837A3 (en) Anti-c10orf54 antibodies and uses thereof
WO2016011306A3 (en) Terminal modifications of polynucleotides
EP3315608A4 (en) Sirna, pharmaceutical composition and conjugate which contain sirna, and uses thereof
EP3259272A4 (en) Fused-ring compounds, pharmaceutical composition and uses thereof
WO2015191945A3 (en) Solid state forms of sofosbuvir
EP3129048A4 (en) Antibodies, pharmaceutical compositions and uses thereof
EP3359193A4 (en) Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
WO2014144295A8 (en) Ceftolozane antibiotic compositions
EP3325608A4 (en) Methods and microorganisms for the production of 1,3-butanediol
WO2016125192A3 (en) Processes for the preparation of dolute-gravir
WO2016038542A3 (en) Solid forms of sofosbuvir
WO2015092810A3 (en) Amorphous form of idelalisib
WO2016009401A3 (en) Preparation of tedizolid phosphate
WO2016092561A3 (en) Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof
IN2014CH00840A (en)
WO2016100615A3 (en) Methods and composition for neutralization of influenza
WO2016061555A3 (en) Novel small molecule anticancer agents
EP3539978A4 (en) Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
WO2016063289A3 (en) Pharmaceutical tablet compositions comprising rifaximin
WO2014009970A3 (en) Linagliptin solid dispersion
EP3262047A4 (en) Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same
WO2016092442A8 (en) Processes for the preparation of crystalline forms of palbociclib acetate

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15734844

Country of ref document: EP

Kind code of ref document: A2